A recently published pooled analysis of NSCLC with PD–L1 TPS ≥50% demonstrated the superiority of combined therapy (OS, 25.0 months vs. 20.9 months; PFS, (9.6 months vs. 7.1 months) (68). The gene discussed is CD274; the disease is non-small cell lung carcinoma.